Sign up to save your podcasts
Or
Share Life Lessons feature show on MS and new drug
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Life Lessons feature show on MS and new drug
HIGHLY ANTICIPATED MEDICINE APPROVED FOR TWO TYPES OF MULTIPLE SCLEROSIS
Life Lessons announces break through news on new drug for MS. Joining us today are
OCREVUS PATIENT: Raquel Martinez, 46-year-old wife and mother of four.NEUROLOGIST/MS SPECIALIST: Dr. Edward Fox, Central Texas Neurology Consultants.
Many people have heard of multiple sclerosis (MS) but aren’t quite sure what it is. MS is a chronic neurological disease that occurs when a person’s immune system attacks their central nervous system – it affects approximately 400,000 people in the U.S. MS can display a mix of unpredictable physical, cognitive or emotional symptoms that vary from person to person and will lead to some level of disability in most people.
In March, the U.S. Food and Drug Administration (FDA) approved OCREVUS™ (ocrelizumab) for relapsing and primary progressive forms of https://mail.google.com/mail/u/0/?tab=wm#m_-8991246538250969379__edn4It is the first FDA-approved MS treatment to target B cells, a type of immune cell that plays a key role in the disease. The approval of OCREVUS is a scientific advancement for the MS community.
The medicine is given once every six months by an intravenous (IV) infusion.iv Side effects associated with OCREVUS included upper respiratory tract infections and infusion reactions.
Patient Raquel Martinez, 46: A working mother of four, was diagnosed with RMS in 2012 after she thought a pinched nerve was the reason her foot went limp while she was running. Her symptoms worsened and she became clumsy and started falling down.
View all episodes
By Rick TocquignyHIGHLY ANTICIPATED MEDICINE APPROVED FOR TWO TYPES OF MULTIPLE SCLEROSIS
Life Lessons announces break through news on new drug for MS. Joining us today are
OCREVUS PATIENT: Raquel Martinez, 46-year-old wife and mother of four.NEUROLOGIST/MS SPECIALIST: Dr. Edward Fox, Central Texas Neurology Consultants.
Many people have heard of multiple sclerosis (MS) but aren’t quite sure what it is. MS is a chronic neurological disease that occurs when a person’s immune system attacks their central nervous system – it affects approximately 400,000 people in the U.S. MS can display a mix of unpredictable physical, cognitive or emotional symptoms that vary from person to person and will lead to some level of disability in most people.
In March, the U.S. Food and Drug Administration (FDA) approved OCREVUS™ (ocrelizumab) for relapsing and primary progressive forms of https://mail.google.com/mail/u/0/?tab=wm#m_-8991246538250969379__edn4It is the first FDA-approved MS treatment to target B cells, a type of immune cell that plays a key role in the disease. The approval of OCREVUS is a scientific advancement for the MS community.
The medicine is given once every six months by an intravenous (IV) infusion.iv Side effects associated with OCREVUS included upper respiratory tract infections and infusion reactions.
Patient Raquel Martinez, 46: A working mother of four, was diagnosed with RMS in 2012 after she thought a pinched nerve was the reason her foot went limp while she was running. Her symptoms worsened and she became clumsy and started falling down.